Any current/future new fundraising through debt or equity?

There is no mention of any current or planned fundraising through debt or equity in the transcript. The company remains debt-free as of December 31, 2025. All capital expenditures are being funded entirely through internal accruals. The company maintains a healthy investible surplus of Rs. 463 crore. No specific plans for new equity or debt issuance were discussed during the call.

Any current/future capex/capital investment/strategic investment?

Estimated CAPEX for the coming year (FY’27) is around Rs. 250-275 crores. CAPEX will be mainly at three locations: Chennai, Amdoshi, and infrastructure developments at Panipat. The EPS Phase 2 expansion is expected to be operational by February-March 2026. No new CAPEX or new business announcements apart from Phase 2 ABS and Haryana projects as of now. ABS plant commissioning delayed due to equipment malfunction; once operational, focus will be on ramping up production and compounding. Capital expenditure is funded entirely through internal accruals; the company remains debt-free. Any future c

Future growth expectations in sales/revenue/volumes?

Volume growth target for FY'27-28 is around 10%, assuming ABS plant commissioning by end of current financial year. Contribution to growth: 3-4% from base business, approximately 7% from ABS operations if started as planned. Focus on ABS compounding business anticipated to provide stability and cushion to earnings. Polystyrene capacities operated at ~80% utilization; demand pickup expected with styrene price stabilization. Strategic CAPEX of Rs. 250-275 crores planned for FY’26 mainly at Chennai, Amdoshi, and Panipat for infrastructure and growth, including EPS Phase 2 starting operati

Future growth expectations in earnings/operating earnings/profits/EPS?

The company anticipates a growth of around 10% in FY’27 and FY’28, assuming the ABS plant becomes operational by the end of the current financial year. Of this 10% growth, approximately 3%-4% is expected from the base business, with the remaining 6%-7% coming from ABS operations. EPS and profits are expected to benefit from the ramp-up of ABS and compounding businesses, which provide more value-added product offerings. Operating EBITDA margin in Q3 FY’26 stood at 5.47%, with potential improvement expected as ABS operations normalize and demand stabilizes. The company maintains a debt-free bala

Current/ Expected Orderbook/ Pending Orders?

Supreme Petrochem has not taken any advance order book for the ABS plant as they want customers to use the product first for application testing. Due to the white color of their ABS material, master batch matching issues caused some delays in sampling and supply. Orders from major OEMs for ABS compounds have started coming in after successful sample matching. Transition period is ongoing; increased utilization in compounding lines expected once ABS plant restarts. No specific timelines disclosed for restarting ABS plant or achieving full utilization. No segment-wise order book numbers were sha

IN US

Sale is live|00:00:00left today

Supreme Petrochem LtdQ4 FY27Chemicals & Petrochemicals

Supreme Petrochem Ltd Q4 FY27 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹740P/E: 39.1Market Cap: ₹13.1K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→Volume growth target for FY'27-28 is around 10%, assuming ABS plant commissioning by end of current financial year.
→Contribution to growth: 3-4% from base business, approximately 7% from ABS operations if started as planned.
→Focus on ABS compounding business anticipated to provide stability and cushion to earnings.
→Polystyrene capacities operated at ~80% utilization; demand pickup expected with styrene price stabilization.
→Strategic CAPEX of Rs. 250-275 crores planned for FY’26 mainly at Chennai, Amdoshi, and Panipat for infrastructure and growth, including EPS Phase 2 starting operations by February/March.
→Expect sequential improvement in performance from Q4 due to stronger OEM demand and stabilized raw material prices.
→Export demand expected to improve post India-EU FTA, enhancing revenue diversification.

Margin guidance

Category 3

→The company anticipates a growth of around 10% in FY’27 and FY’28, assuming the ABS plant becomes operational by the end of the current financial year.
→Of this 10% growth, approximately 3%-4% is expected from the base business, with the remaining 6%-7% coming from ABS operations.
→EPS and profits are expected to benefit from the ramp-up of ABS and compounding businesses, which provide more value-added product offerings.
→Operating EBITDA margin in Q3 FY’26 stood at 5.47%, with potential improvement expected as ABS operations normalize and demand stabilizes.
→The company maintains a debt-free balance sheet and will fund growth CAPEX (~Rs. 250-275 crores for FY’27) internally, supporting steady growth without financing constraints.
→Sequential improvement in performance is expected in Q4 and beyond, driven by stronger OEM demand and stabilized raw material prices.

3 more insights locked — sign up free to unlock

Fundraise plans

→There is no mention of any current or planned fundraising through debt or equity in the transcript.
→The company remains debt-free as of December 31, 2025.
→All capital expenditures are being funded entirely through internal accruals.
→The company maintains a healthy investible surplus of Rs. 463 crore.
→No specific plans for new equity or debt issuance were discussed during the call.

Order book

→Supreme Petrochem has not taken any advance order book for the ABS plant as they want customers to use the product first for application testing.
→Due to the white color of their ABS material, master batch matching issues caused some delays in sampling and supply.
→Orders from major OEMs for ABS compounds have started coming in after successful sample matching.
→Transition period is ongoing; increased utilization in compounding lines expected once ABS plant restarts.
→No specific timelines disclosed for restarting ABS plant or achieving full utilization.
→No segment-wise order book numbers were shared publicly during the call.

Capex plans

Yes

→Estimated CAPEX for the coming year (FY’27) is around Rs. 250-275 crores.
→CAPEX will be mainly at three locations: Chennai, Amdoshi, and infrastructure developments at Panipat.
→The EPS Phase 2 expansion is expected to be operational by February-March 2026.
→No new CAPEX or new business announcements apart from Phase 2 ABS and Haryana projects as of now.
→ABS plant commissioning delayed due to equipment malfunction; once operational, focus will be on ramping up production and compounding.
→Capital expenditure is funded entirely through internal accruals; the company remains debt-free.
→Any future capital costs related to repairs on ABS plant equipment are covered under warranty, so no incremental CAPEX expected there.

How does Supreme Petrochem Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

1Supreme Petrochem Ltd

Rev 3Mar 3

See full Chemicals & Petrochemicals sector rankings

Want more stocks like Supreme Petrochem Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio